<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256838</url>
  </required_header>
  <id_info>
    <org_study_id>PBB00501</org_study_id>
    <nct_id>NCT03256838</nct_id>
  </id_info>
  <brief_title>Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis</brief_title>
  <official_title>A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panion &amp; BF Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panion &amp; BF Biotech Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the long-term safety and effectiveness of Nephoxil® for the treatment of
      hyperphosphatemia in patients with ESRD undergoing dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, prospective, long term, Phase IV study to assess the safety and
      efficacy of Nephoxil® in subjects with ESRD on dialysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>13 months</time_frame>
    <description>Number of subjects with treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of subjects with treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphorus</measure>
    <time_frame>13 months</time_frame>
    <description>Serum Phosphorus will be assessed by time-course changes of serum phosphorus levels and proportion of subjects achieved target range of serum phosphorus (&gt;=3.5 mg/dL and &lt;=5.5. mg/dL) from baseline to the end-of-treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum calcium</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of serum calcium from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intact plasma parathyroid hormone (iPTH)</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of intact plasma parathyroid hormone (iPTH) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ferritin</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of ferritin from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transferring saturation (TSAT) percentage</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of transferring saturation (TSAT) percentage from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum iron</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of serum iron from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total iron-binding capacity (TIBC)</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of total iron-binding capacity (TIBC) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of hemoglobin from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose of IV iron</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of dose of IV iron from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose of erythropoiesis stimulating agents (ESA)</measure>
    <time_frame>13 months</time_frame>
    <description>Time-course changes of dose of erythropoiesis stimulating agents (ESA) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>13 months</time_frame>
    <description>Prescribed dose and the dose actually taken at each time point will be calculated.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>End-stage Renal Disease</condition>
  <condition>Phosphorus Metabolism Disorders</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Ferric citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Citrate</intervention_name>
    <description>Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.</description>
    <arm_group_label>Ferric citrate</arm_group_label>
    <other_name>Nephoxil® Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is ≧ 18 years of age on the day of signing informed consent or other age required by
             local regulation

          2. Willing and able to provide written informed consent

          3. ESRD patients who is undergoing hemodialysis 3 times per week and is considered
             necessary to receive medication for hyperphosphatemia by his/her treating physician

          4. Serum ferritin &lt;1000 ng/mL and transferrin saturation (TSAT) &lt; 50% at the Enrollment
             Visit

          5. Women of child-bearing potential (WOCBP [defined as women ≤ 50 years of age with a
             history of amenorrhea for &lt; 12 months prior to study entry]) who is willing to use an
             effective form of contraception during study participation

        Exclusion Criteria:

          1. Has any known contraindication to ferric citrate according to locally approved
             prescribing information, include but not limited to the following criteria:

             i. Is allergic to ferric citrate ii. Has hypophosphatemia iii. Has hemochromatosis or
             iron overload syndromes iv. Has active severe GI disorders

          2. Has parathyroidectomy (PTx) or percutaneous ethanol injection therapy (PEIT) within 3
             months prior to Enrollment Visit or serum calcium &lt; 7 mg/dL at the Enrollment Visit

          3. Has participated in another interventional study for any investigational agent or
             device within 30 days prior to enrollment

          4. Is currently pregnant or breastfeeding

          5. Other unstable medical condition or psychiatric conditions that is considered
             unsuitable for this study per Investigator's clinical judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai-Szu Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy Chiang</last_name>
    <phone>+886-2-2655-8218</phone>
    <phone_ext>302</phone_ext>
    <email>cchiang@pbf.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond Chuang, MS, PMP</last_name>
    <phone>+886-2-2655-8218</phone>
    <phone_ext>303</phone_ext>
    <email>rchuang@pbf.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Wen Chiu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yi-Wen Chiu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Te Lee, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chien-Te Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Chang Lee, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Chang Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Sen Peng, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yu-Sen Peng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Ju Wu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ming-Ju Wu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Shiou Wu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ming-Shiou Wu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11042</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai-Szu Wu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mai-Szu Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11101</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Gang Leu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jyh-Gang Leu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Der-Cherng Tarng, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Der-Cherng Tarng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>August 20, 2017</last_update_submitted>
  <last_update_submitted_qc>August 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Citric Acid</keyword>
  <keyword>Ferric Compounds</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Calcium Chelating Agents</keyword>
  <keyword>Chelating Agents</keyword>
  <keyword>Sequestering Agents</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Phosphorus Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Chelating Agents</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

